NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-DE-16-006 from the NIH Guide for Grants and Contracts
Notice NOT-CA-17-003 from the NIH Guide for Grants and Contracts
Notice NOT-MD-16-011 from the NIH Guide for Grants and Contracts
Notice of NHLBI Participation in PAS-15-168 "New Directions in Hematology Research (SHINE-II) (R01)"
Notice NOT-HL-16-461 from the NIH Guide for Grants and Contracts
Notice NOT-AG-16-081 from the NIH Guide for Grants and Contracts
Notice NOT-HL-16-460 from the NIH Guide for Grants and Contracts
Notice NOT-AI-17-006 from the NIH Guide for Grants and Contracts
Notice NOT-DA-17-003 from the NIH Guide for Grants and Contracts
Notice NOT-HL-16-463 from the NIH Guide for Grants and Contracts
Notice NOT-CA-17-001 from the NIH Guide for Grants and Contracts
Notice NOT-LM-17-002 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-17-051 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIGMS R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences and Courses for Skills Development. Applications are encouraged from research-intensive institutions that propose to equip recent baccalaureate science graduates from diverse backgrounds underrepresented in biomedical sciences with the necessary knowledge and skills to pursue Ph.D. degrees in these fields. The program provides support for extensive research experiences and well-designed courses for skills development aimed at preparing individuals from underrepresented backgrounds to complete doctoral degrees.
Funding Opportunity PAR-17-052 from the NIH Guide for Grants and Contracts. This NIA Research Career Enhancement Award (K18) program invites applications from qualified researchers to acquire training and career development experiences that close expertise gaps in data science and in drug discovery. The goal of the program is to allow Alzheimer's Disease (AD) researchers to expand their expertise to become more effective in leading cross-disciplinary, translational, team-science projects in AD or AD-related dementias (ADRD). This award will also allow data scientists to redirect their expertise toward the study of AD and ADRD.
Funding Opportunity RFA-DK-16-036 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support the NIDDK Diabetic Complications Consortium Coordinating Unit (DiaComp-CU). The DiaComp-CU will continue to enhance and maintain the DiaComp website, and will provide administrative oversight for consortium meetings and opportunity pool programs.
Funding Opportunity RFA-DK-16-034 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support the Coordinating Unit for the NIDDK Mouse Metabolic Phenotyping Centers Consortium (MMPC-CU). The MMPC-CU will continue to enhance and maintain the MMPC website and database, and will provide administrative support needed to enhance MMPC services, meetings, and opportunity pool programs.
Funding Opportunity RFA-HD-17-001 from the NIH Guide for Grants and Contracts. The objective of this FOA is to establish expert panels that will select genes and genomic variants associated with diseases or conditions of high priority to NICHD and systematically determine their clinical significance and utility for diagnosis and treatment of these diseases or conditions. The Genomic Clinical Variant Expert Curation Panels funded through this FOA are expected to utilize the NHGRI Clinical Genomics Resource (ClinGen) and the NCBI ClinVar tools and informatics infrastructure to determine the strength of evidence supporting the clinical significance or actionability of the selected genes and variants that will support development of clinical practice guidelines.
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21)
Funding Opportunity RFA-CA-17-010 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology.
Funding Opportunity RFA-CA-17-011 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Funding Opportunity RFA-CA-17-012 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Funding Opportunity RFA-CA-17-013 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.